Provectus Biopharmaceuticals Inc (PVCT) USD0.001
Sell:$0.07Buy:$0.07
$0.00
(4.50%)
- This stock can be held in a
Stocks and Shares ISA
Fund and Share Account$0.00
(4.50%)$0.00
(4.50%)Company Information
About this company
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
Key people
Key facts
- EPICPVCT
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS74373P1084
- Market cap$32.15m
- Employees6
- Shares in issue420.28m
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.